A number of other analysts have also commented on the company. Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. They set an outperform rating and a $128.00 price target on the stock. Cowen reaffirmed a buy rating and issued a $120.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. UBS Group raised their target price on Alnylam Pharmaceuticals from $95.00 to $96.00 and gave the stock a neutral rating in a research report on Wednesday, September 4th. Nomura set a $62.00 price target on Alnylam Pharmaceuticals and gave the company a sell rating in a research report on Tuesday, October 8th. Finally, BMO Capital Markets upped their price target on Alnylam Pharmaceuticals from $128.00 to $138.00 and gave the company an outperform rating in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $114.58.
Shares of ALNY opened at $123.76 on Wednesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.22 and a current ratio of 5.38. Alnylam Pharmaceuticals has a 52 week low of $60.27 and a 52 week high of $125.72. The stock has a market capitalization of $13.80 billion, a price-to-earnings ratio of -16.35 and a beta of 2.46. The stock has a fifty day moving average of $98.68 and a 200-day moving average of $81.91.
In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 15,000 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $91.71, for a total transaction of $1,375,650.00. Following the transaction, the director now directly owns 250,633 shares in the company, valued at approximately $22,985,552.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, President Barry E. Greene sold 58,913 shares of the stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $89.99, for a total value of $5,301,580.87. Following the transaction, the president now owns 111,851 shares in the company, valued at $10,065,471.49. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,773 shares of company stock valued at $18,988,930. Company insiders own 3.60% of the company’s stock.
Several large investors have recently added to or reduced their stakes in ALNY. Amundi Pioneer Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 12.6% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 149,659 shares of the biopharmaceutical company’s stock worth $13,986,000 after purchasing an additional 16,733 shares during the period. Commerzbank Aktiengesellschaft FI boosted its holdings in Alnylam Pharmaceuticals by 166.3% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 6,110 shares of the biopharmaceutical company’s stock worth $443,000 after acquiring an additional 3,816 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $470,000. Steward Partners Investment Advisory LLC bought a new position in Alnylam Pharmaceuticals in the second quarter worth approximately $83,000. Finally, Creative Planning acquired a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $1,538,000. Institutional investors own 95.79% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Featured Article: How big is the FinTech market?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.